FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a mouse whose genome contains a mutation in the penultimate exon of the fibrillin-1 gene, to its embryonic stem (ES) cell, as well as to a method for producing the above mouse. Also disclosed is a method for screening a compound for activity which reduces symptoms similar to those of congenital lipodystrophy involving using said mouse.
EFFECT: invention enables effective modelling of neonatal progeroid syndrome with congenital lipodystrophy.
62 cl, 13 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF IMMUNOTHERAPY OF PATIENTS WHOSE TUMORS ARE CHARACTERIZED BY HIGH LOAD OF PASSENGER GENE MUTATIONS | 2018 |
|
RU2819454C2 |
| REDUCED NICOTINE CONVERSION INTO NORNICOTINE IN PLANTS | 2015 |
|
RU2733837C2 |
| COMPOSITION FOR RELIEVING OR TREATING PAIN | 2017 |
|
RU2725830C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| NEW CAPSID PROTEINS OF ADENO-ASSOCIATED VIRUS | 2017 |
|
RU2779318C2 |
| HERPES SIMPLEX SYNCYTIAL ONCOLYTIC MUTANTS AS POWERFUL THERAPEUTIC AGENTS FOR TREATING CANCER | 2020 |
|
RU2821999C2 |
| METHODS OF OBTAINING INDUSTRIAL PRODUCTS FROM PLANT LIPIDS | 2015 |
|
RU2743384C2 |
| IMMUNOGLOBULINS CONJUGATED WITH LYSINE | 2017 |
|
RU2762939C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
